An M spike is a sharp, narrow peak that appears on a blood test called serum protein electrophoresis (SPEP). It signals that one clone of plasma cells is producing a large amount of a single, identical antibody protein. In multiple myeloma, this abnormal protein is the direct, measurable footprint of the cancer, and tracking its size is central to diagnosis, staging, and monitoring treatment.
How the M Spike Shows Up on a Blood Test
Protein electrophoresis works by separating your blood proteins into groups based on their electrical charge. In a healthy person, the result looks like a series of gentle hills and valleys, with the broadest hill in the gamma region, where antibodies live. That hill is broad because your immune system normally produces thousands of slightly different antibodies, each made by a different plasma cell.
When a single plasma cell becomes cancerous and multiplies out of control, all its copies churn out the exact same antibody. On the electrophoresis tracing, that flood of identical protein creates a tall, narrow spike rather than a gentle curve. That spike is the M spike (the “M” stands for monoclonal, meaning from one clone). It most often appears in the gamma region, but IgA-type proteins frequently migrate into the beta region, and in rare cases the spike can appear as far over as the alpha-2 zone.
Types of M Protein
Antibodies come in different classes, and the class produced by myeloma cells matters for both detection and prognosis. In large patient series, IgG myeloma accounts for roughly 52 to 54% of cases, making it the most common type. IgA follows at about 21 to 22%. Around 16% of patients produce only the small “light chain” portion of an antibody without the heavier component, a form sometimes called light chain myeloma. IgD and IgM types are rare, together making up about 2.5% of cases.
In light chain myeloma, the abnormal protein is small enough to pass through the kidneys and show up in urine rather than accumulating in the blood. About 20% of myeloma patients produce only these light chains (historically called Bence Jones proteins). Because a standard blood SPEP may not catch them, doctors also run urine protein electrophoresis and a serum free light chain test to avoid missing the disease.
A small subset, roughly 3% of all myeloma cases, is called non-secretory myeloma. These patients have cancerous plasma cells in the bone marrow but no detectable M protein in blood or urine, so diagnosis relies on bone marrow biopsy and imaging instead.
What the M Spike Level Means for Diagnosis
The size of the M spike, measured in grams per deciliter (g/dL), helps distinguish between conditions that exist on a spectrum from harmless to cancerous. For context, total globulin levels in a healthy adult typically fall between 2.0 and 3.5 g/dL.
The International Myeloma Working Group uses specific thresholds:
- MGUS (monoclonal gammopathy of undetermined significance): M protein at or below 3 g/dL, fewer than 10% plasma cells in the bone marrow, and no organ damage. This is a precancerous condition that most people live with and never develop myeloma from.
- Smoldering myeloma: M protein at 3 g/dL or above, or bone marrow plasma cells between 10% and 60%, but still no symptoms or organ damage. This is an intermediate stage that requires monitoring.
- Active multiple myeloma: At least 10% plasma cells in the bone marrow plus evidence of organ damage, sometimes summarized as the CRAB criteria: high calcium, kidney problems, anemia, or bone lesions. Active myeloma can also be diagnosed when certain biomarkers hit extreme thresholds, such as bone marrow plasma cells reaching 60% or higher, regardless of the M spike size.
The M spike alone doesn’t determine the diagnosis. A person with a small spike but significant bone destruction still has active myeloma, while someone with a large spike and no organ damage may be classified as smoldering.
Tracking Treatment With the M Spike
Once treatment begins, the M spike becomes the primary yardstick for measuring how well therapy is working. Doctors repeat the blood test at regular intervals and compare the current spike to the level at diagnosis. The international response criteria define clear benchmarks:
- Partial response (PR): The M protein in blood drops by at least 50%, and urinary M protein drops by at least 90% or falls below 200 mg over 24 hours.
- Very good partial response (VGPR): The M spike disappears from the standard electrophoresis tracing but is still detectable by a more sensitive test called immunofixation. Alternatively, the blood M protein drops by 90% or more while urine levels fall below 100 mg per 24 hours.
- Complete response: No M protein detectable by immunofixation in blood or urine, combined with fewer than 5% plasma cells in the bone marrow.
For patients whose myeloma produces only free light chains rather than a full antibody, doctors track the ratio between involved and uninvolved light chains instead. A 50% drop in the difference qualifies as a partial response, and a 90% drop qualifies as a very good partial response.
Why the M Spike Matters Beyond Diagnosis
The M spike isn’t just a one-time diagnostic finding. Its behavior over time tells you whether the disease is stable, responding to treatment, or relapsing. A rising M spike after a period of stability is often the earliest sign that myeloma is becoming active again, sometimes appearing months before symptoms return. That early warning gives doctors a window to adjust treatment.
The type and size of the monoclonal protein at diagnosis also factor into risk assessment. Larger spikes at diagnosis generally correlate with a higher burden of disease. The immunoglobulin class matters too: IgA myeloma, for instance, tends to behave differently from IgG myeloma in ways that can influence treatment planning and outlook. Serum free light chain ratios add another layer of prognostic information, particularly in patients whose disease doesn’t produce a large, easily measurable spike on standard electrophoresis.
Because the M spike is so central to managing myeloma, you can expect regular blood draws throughout treatment and long-term follow-up. Understanding what the number represents, and how the benchmarks work, makes it easier to interpret your lab results and have informed conversations about how your treatment is going.